Published in BMC Bioinformatics on June 16, 2010
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res (2012) 1.22
Statistical considerations for analysis of microarray experiments. Clin Transl Sci (2011) 1.00
Fast random permutation tests enable objective evaluation of methods for single-subject FMRI analysis. Int J Biomed Imaging (2011) 0.90
Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther (2014) 0.84
CFMDS: CUDA-based fast multidimensional scaling for genome-scale data. BMC Bioinformatics (2012) 0.83
GPUmotif: an ultra-fast and energy-efficient motif analysis program using graphics processing units. PLoS One (2012) 0.79
Next generation distributed computing for cancer research. Cancer Inform (2015) 0.76
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Many-core algorithms for statistical phylogenetics. Bioinformatics (2009) 6.70
High-throughput sequence alignment using Graphics Processing Units. BMC Bioinformatics (2007) 5.56
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst (2010) 4.80
CUDA compatible GPU cards as efficient hardware accelerators for Smith-Waterman sequence alignment. BMC Bioinformatics (2008) 3.71
Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res (2009) 3.58
Sample size calculation for multiple testing in microarray data analysis. Biostatistics (2005) 2.84
CUDASW++: optimizing Smith-Waterman sequence database searches for CUDA-enabled graphics processing units. BMC Res Notes (2009) 1.96
Accelerating epistasis analysis in human genetics with consumer graphics hardware. BMC Res Notes (2009) 1.58
The gputools package enables GPU computing in R. Bioinformatics (2009) 1.44
A multiple testing procedure to associate gene expression levels with survival. Stat Med (2005) 1.22
Statistical challenges in preprocessing in microarray experiments in cancer. Clin Cancer Res (2008) 1.19
Highly accelerated feature detection in proteomics data sets using modern graphics processing units. Bioinformatics (2009) 1.17
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol (2006) 4.91
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol (2003) 3.58
Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med (2005) 2.73
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol (2009) 2.56
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol (2013) 2.50
Retracted Alveolar macrophages from overweight/obese subjects with asthma demonstrate a proinflammatory phenotype. Am J Respir Crit Care Med (2012) 2.39
The Society for Clinical Trials supports United States legislation mandating trials registration. Position paper. Clin Trials (2004) 2.21
Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer. J Thorac Oncol (2015) 2.17
Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev (2008) 1.99
A distribution-free test of constant mean in linear mixed effects models. Stat Med (2008) 1.97
Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis (2005) 1.91
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma (2008) 1.91
Nonparametric inference on median residual life function. Biometrics (2007) 1.90
Accuracy of ROPtool vs individual examiners in assessing retinal vascular tortuosity. Arch Ophthalmol (2007) 1.81
Admissible two-stage designs for phase II cancer clinical trials. Stat Med (2004) 1.77
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol (2009) 1.75
Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol (2003) 1.70
Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg (2003) 1.58
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood (2011) 1.55
Mutational hotspots in the mitochondrial genome of lung cancer. Biochem Biophys Res Commun (2011) 1.54
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res (2012) 1.50
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica (2011) 1.48
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer (2013) 1.48
Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clin Trials (2008) 1.48
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol (2008) 1.45
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma (2011) 1.44
Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol (2010) 1.40
Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radic Biol Med (2007) 1.37
Early and late administration of MnTE-2-PyP5+ in mitigation and treatment of radiation-induced lung damage. Free Radic Biol Med (2010) 1.35
A retrospective analysis of facial fracture etiologies. Ann Plast Surg (2008) 1.33
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant (2011) 1.29
Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg (2003) 1.28
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res (2011) 1.26
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res (2012) 1.22
Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis (Edinb) (2011) 1.22
A multiple testing procedure to associate gene expression levels with survival. Stat Med (2005) 1.22
Gradient lasso for Cox proportional hazards model. Bioinformatics (2009) 1.21
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer (2012) 1.21
Statistical challenges in preprocessing in microarray experiments in cancer. Clin Cancer Res (2008) 1.19
Growth hormone mitigates against lethal irradiation and enhances hematologic and immune recovery in mice and nonhuman primates. PLoS One (2010) 1.13
Selection bias, phase II trials, and the FDA accelerated approval process. J Natl Cancer Inst (2003) 1.12
Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant (2011) 1.12
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol (2007) 1.11
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest (2004) 1.10
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther (2010) 1.08
Appropriate design of prospective studies. J Clin Oncol (2012) 1.05
Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol (2007) 1.04
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg (2013) 1.03
P-value calculation for multistage phase II cancer clinical trials. J Biopharm Stat (2006) 1.02
A permutation-based multiple testing method for time-course microarray experiments. BMC Bioinformatics (2009) 1.00
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res (2002) 1.00
Statistical considerations for analysis of microarray experiments. Clin Transl Sci (2011) 1.00
Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes. Genet Epidemiol (2013) 1.00
A parametric model for long-term follow-up data from phase III breast cancer clinical trials. Stat Med (2003) 0.99
Rank tests for clustered survival data when dependent subunits are randomized. Stat Med (2006) 0.98
Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and the relevance of spiritual well-being--a Hoosier Oncology Group Study. J Clin Oncol (2003) 0.98
Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis. BMJ (2004) 0.98
Loss of β-catenin triggers oxidative stress and impairs hematopoietic regeneration. Genes Dev (2014) 0.95
Managing accrual in cooperative group clinical trials. J Clin Oncol (2004) 0.95
Designing phase II studies in cancer with time-to-event endpoints. Clin Trials (2008) 0.95
A Risk-prediction Model Based on Lymph-node Metastasis for Incorporation Into a Treatment Algorithm for Signet Ring Cell-type Intramucosal Gastric Cancer. Ann Surg (2016) 0.92
Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents. Medicine (Baltimore) (2016) 0.92
The long-term clinical course of patients with cutaneous melanoma. Cancer (2002) 0.90
The importance of identifying and validating prognostic factors in oncology. Semin Oncol (2010) 0.90
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood (2011) 0.89
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol Cancer Ther (2010) 0.89
A polymorphism within the promoter of the TGFβ1 gene is associated with radiation sensitivity using an objective radiologic endpoint. Int J Radiat Oncol Biol Phys (2011) 0.89
Postoperative prognosis prediction of pancreatic cancer with seven microRNAs. Pancreas (2015) 0.88
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs (2013) 0.88
Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism. Thromb Res (2011) 0.88
SNPpy--database management for SNP data from genome wide association studies. PLoS One (2011) 0.87
Data monitoring and large apparent treatment effects. Control Clin Trials (2004) 0.87
Effect of dropouts on sample size estimates for test on trends across repeated measurements. J Biopharm Stat (2005) 0.87
Between-arm comparisons in randomized Phase II trials. J Biopharm Stat (2009) 0.87
Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test. Stat Med (2013) 0.87
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest New Drugs (2013) 0.86
Power and sample size calculations for SNP association studies with censored time-to-event outcomes. Genet Epidemiol (2012) 0.86
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics (2013) 0.85
Thrombospondin-1 and thrombospondin-2 mRNA and TSP-1 and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 and COL3A1 and to the collagen cross-link hydroxyproline. Reprod Sci (2007) 0.85
Clinical trials data collection: when less is more. J Clin Oncol (2010) 0.85
Medulloblastoma and birth date: evaluation of 3 U.S. datasets. Arch Environ Health (2004) 0.84
Response rate as an endpoint in clinical trials. J Natl Cancer Inst (2007) 0.84
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002). Biol Blood Marrow Transplant (2010) 0.84
Physician self-referral of lumbar spine MRI with comparative analysis of negative study rates as a marker of utilization appropriateness. AJR Am J Roentgenol (2012) 0.84